Tetrasol

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tetrasol

Tetrasol, defined by its primary composition, is an antibiotic medication classified within the tetracycline class of anti-infective agents. Its fundamental identity is tied to its main component, Tetracycline Hydrochloride, which is utilized to help manage and control various systemic bacterial infections.


Quick Facts

Property Description
Active ingredient Tetracycline Hydrochloride
Form Soluble Powder
Pharmacological class Tetracycline Antibiotic
Common use Control of bacterial infections
Origin Semi-synthetic derivative

What Type of Medicine is Tetrasol?

Tetrasol is recognized as a broad-spectrum antibacterial agent, indicating its effectiveness against a wide variety of harmful bacteria, encompassing both Gram-positive and Gram-negative types. This medication belongs to the tetracycline group. The active ingredient, Tetracycline, is classified as a semi-synthetic derivative, having been initially derived from naturally occurring microorganisms belonging to the Streptomyces genus. The active ingredient is recognized for its efficacy against infections caused by susceptible bacterial species.


Understanding the General Purpose of Tetrasol

The general purpose of Tetrasol is to help control the growth and spread of bacterial populations within the body by preventing them from multiplying. Its therapeutic effect is primarily bacteriostatic, meaning the drug's fundamental action is to halt the multiplication of susceptible bacteria by interfering with their protein synthesis. Tetracycline works by inhibiting bacterial protein synthesis via binding to the 30S ribosomal subunit. By functionally impeding the bacterial reproductive cycle, the drug assists the host body's natural immune system in overcoming the burden of the existing infection.


Composition and Available Form

Tetrasol is defined by its single active ingredient, Tetracycline Hydrochloride. This preparation is typically provided in the form of a Soluble Powder, which is specifically designed to be dissolved in a liquid vehicle prior to oral administration. This Soluble Powder formulation is a distinguishing feature, containing the active compound alongside necessary water-soluble excipients, which facilitates its uniform dispersal and subsequent systemic delivery to exert its broad-spectrum antibacterial effect.

Regulatory References

  1. WHO List of Essential Medicines

What side effects are possible with Tetrasol?

Possible side effects and safety information

The safety profile of Tetrasol (Tetracycline Hydrochloride) is formally defined by regulatory agencies based on the types of adverse reactions documented during clinical use and post-marketing surveillance. These reactions are categorized by the systems affected and their relative frequency, such as common, uncommon, or rare.

Adverse Reaction Classifications

Adverse reactions commonly listed in official regulatory documents include disturbances of the gastrointestinal system (e.g., nausea, vomiting, diarrhea, anorexia) and effects on the skin and subcutaneous tissue, notably photosensitivity (an exaggerated sunburn reaction).

Other potential effects, classified as less common or rare, have been reported across other system-organ classes, including the blood and lymphatic system (e.g., thrombocytopenia, anemia), the nervous system (e.g., headache), and the hepatobiliary system (abnormal liver function). Rare but serious hypersensitivity reactions, such as anaphylaxis, are also documented.

Serious Safety Considerations and Restrictions

Official labeling defines specific serious adverse reactions, including Intracranial Hypertension (IH), also known as pseudotumor cerebri, and Clostridioides difficile-associated diarrhea (CDAD), which can be severe.

Regulatory safety information also includes strict restrictions for certain populations due to the risk of irreversible effects. The drug is generally contraindicated for use in children under 8 years of age and during the last half of pregnancy due to the potential for permanent tooth discoloration and enamel hypoplasia in the developing teeth. Specific restrictions also exist concerning use in individuals with severe hepatic or renal impairment.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Tetrasol (Tetracycline Hydrochloride) may lead to severe systemic toxicity, necessitating immediate emergency medical intervention as outlined in regulatory documentation.

Documented Manifestations and Severe Outcomes

Official labeling documents that overdose or accumulation, particularly in individuals with impaired renal function, carries the potential for liver failure and in rare cases, death. Signs of toxicity may include anti-anabolic effects resulting in laboratory abnormalities such as azotaemia and hyperphosphataemia. In adults, overdose may manifest as benign intracranial hypertension (Pseudotumor cerebri), and in infants, this may present as bulging fontanelles.

Emergency Actions Mandated by Regulators

Regulatory authorities explicitly mandate that individuals must seek emergency medical attention immediately for any suspected overdose or call a Poison Help line. Immediate contact with emergency services (911) is required if the affected person collapses, has a seizure, experiences trouble breathing, or cannot be awakened.

Management of Tetrasol overdose is symptomatic and supportive, as no specific antidote is known. Officially described procedural steps include performing gastric lavage as soon as possible and ensuring high fluid intake is maintained. Hospital monitoring of key organ systems, including hepatic and renal function, is required.

Therapeutic Uses of Tetrasol

What Tetrasol Treats: Main Uses and Benefits

Tetrasol is commonly used across several therapeutic domains to manage and address a broad spectrum of infections and inflammatory conditions characterized by periods of heightened symptoms caused by susceptible bacteria. These applications include infections of the respiratory tract, skin, eye, lymphatic, intestinal, genital, and urinary systems.

It is applied in clinical settings that involve acute or unstable symptom patterns, such as certain pneumonias and acute exacerbations of chronic bronchitis. It is relevant for managing symptoms of serious infections, including those spread by vectors (like Rocky Mountain Spotted Fever and Typhus), and is relevant for easing symptoms associated with conditions like Plague and Cholera. By addressing the bacterial cause, it provides support that helps ease the overall symptom burden associated with fever, chills, and systemic imbalance.

In addition, Tetrasol is relevant for easing the symptoms related to inflammatory or irritative states, such as severe acne and rosacea. This contributes to improved comfort during periods of heightened symptoms by easing the symptom load related to lesions and redness that interfere with daily functioning.


Quick Fact: Relief for Systemic and Skin Symptoms
Tetrasol helps address systemic symptoms of fever and malaise, and is applied in addressing the symptom load related to lesions in conditions like severe acne.

Regulatory References

  1. NIH MedlinePlus overview of Tetracycline

Eligibility and Restrictions for Use

Tetrasol (Tetracycline Hydrochloride) eligibility is strictly defined by regulatory guidelines to protect vulnerable populations and those with specific health conditions.

Populations for Whom Use is Contraindicated

Use is prohibited for the following populations based on official regulatory labeling:

  • Individuals with known hypersensitivity to tetracycline or any related tetracycline-class antibiotics.
  • Children under 8 years of age due to the documented risk of permanent tooth discoloration and enamel hypoplasia during tooth development, except in specific life-threatening situations.
  • Pregnant individuals, particularly during the last half of pregnancy (second and third trimesters), due to the risk of fetal skeletal impairment and permanent tooth discoloration.
  • Patients taking concurrent systemic retinoids (e.g., Isotretinoin) because the combination increases the risk of Intracranial Hypertension.
  • Patients with severe renal failure.

Age-Related and Conditional Eligibility

Population Group Regulatory Status
Children geq 8 years Generally eligible for approved indications.
Lactating individuals Use is generally avoided as the drug passes into breast milk, although some sources note minimal absorption by the infant.
Renal/Hepatic Impairment Conditional use; non-severe impairment requires caution and possible dose adjustment due to the risk of systemic accumulation and potential toxicity. Severe impairment is a contraindication.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Tetrasol’s official interaction profile is defined by pharmacodynamic, pharmacokinetic, and absorption-based patterns documented in regulatory sources.

Category Details (Official Regulatory Information)
Medicinal product categories with documented interactions Anticoagulants, Bactericidal Antibiotics (Penicillins), Antacids, Iron Preparations, Systemic Retinoids, and select Anticonvulsants (Barbiturates, Carbamazepine, Phenytoin).
Mechanistic basis of interactions Impairment of absorption (chelation) with metallic cations, depression of plasma prothrombin activity, interference with bactericidal action, and decrease in drug half-life.
Timing-based interaction rules Administration must be separated from Antacids, Iron-containing preparations, and calcium-containing foods (including dairy products) to mitigate documented impairment of absorption.
Interaction-related restrictions Concomitant use is contraindicated with the systemic retinoid Isotretinoin (due to risk of Intracranial Hypertension) and with Methoxyflurane (due to risk of fatal renal toxicity).

Official regulatory documents classify co-administration with enzyme inducers (e.g., Barbiturates) as leading to a decrease in the half-life of Tetrasol. The drug is documented to reduce the efficacy of Oral Contraceptives and may require a downward dosage adjustment for concurrently administered anticoagulant therapy due to depression of plasma prothrombin activity. Population-specific notes document that toxicity risks are officially heightened in patients with significantly impaired renal function, and the risk of Intracranial Hypertension is greater in overweight women of childbearing age.

Mechanism of Action

Targeted Inhibition of Protein Assembly

Tetrasol exerts its primary action as a specific inhibitor of bacterial protein synthesis. The molecule acts by binding reversibly and with high affinity to the 30 S ribosomal subunit of susceptible bacteria, which is the complex required for translation. This interaction physically blocks the entry of new mathbfaminoacyl-tRNA molecules, thereby preventing the assembly of necessary proteins.


Selective Bacteriostatic Mechanism

The mechanism exploits structural differences between prokaryotic (30 S) and host eukaryotic (80 S) ribosomes, resulting in selective toxicity. By stopping protein elongation, the drug arrests bacterial cell growth, leading to a bacteriostatic state which restricts the rate of cell population increase. This functional arrest of proliferation is the key physiological consequence of the mechanism.


Constraints on Mechanism Efficacy

The drug's mechanism is functionally constrained by specific bacterial defenses. These include active efflux pumps that reduce the drug's concentration inside the bacterial cell, and the production of ribosomal protection proteins which displace the drug from its 30 S target and interfere with drug binding at the target.

Dosage and Administration Information

How to use Tetrasol

Tetrasol, defined by its active ingredient Tetracycline Hydrochloride, is approved for oral administration for systemic delivery. The usage pattern is characterized by divided daily dosing, requiring the medicine to be taken two to four times daily (b.i.d. to q.i.d.). The standard total daily dose for adults is typically 1 gram, administered in increments ranging from 250 mg up to 500 mg per dose for more severe needs. For long-term conditions like acne, the regimen may shift to a maintenance range of 125 mg to 500 mg daily or involve intermittent therapy.


Contextual Administration Rules

Adherence to strict timing rules is necessary to ensure adequate absorption. The medication must be taken on an empty stomach, observing the constraint of one hour before or two hours after a meal. The dose must also be separated from all cation-containing substances by a minimum of two hours. This restriction includes products such as milk, dairy, antacids, and preparations containing iron or zinc. Because the preparation is a Soluble Powder, it requires dissolution in a liquid vehicle prior to ingestion. Ingestion must occur with an adequate volume of fluid while maintaining an upright posture (sitting or standing) to reduce the potential for irritation.


Duration and Specific Adjustments

Therapy duration is defined by the type and resolution of the condition, generally continuing for at least 24 to 48 hours after symptoms have subsided. For certain types of infections, a minimum course of ten days is officially specified. Dosing requires modification for certain patient groups: the total daily dosage must be decreased or the interval between doses must be extended for patients with impaired kidney function. For pediatric patients over eight years of age, the dose is calculated based on body weight (typically 25 to 50 mg/kg per day), divided into four equal doses.

Recent Clinical Evidence

Tetrasol: Recent Clinical Evidence

The research on Tetrasol (Tetracycline Hydrochloride) has been conducted over several decades, focusing primarily on the study context of bacterial infections and inflammatory skin conditions. This overview describes the research landscape without providing medical advice or instructions.


Evidence for Use in Acute Systemic Bacterial Infections

Research examining acute systemic bacterial infections has utilized Retrospective Comparative Studies and Clinical Efficacy Cohorts. These studies monitored outcomes related to patient survival and clinical resolution, particularly for severe, susceptible infections. Long-term outcomes describing the measured patterns after the acute phase are generally not well characterized, and research continues to focus on antimicrobial resistance (AMR) concerns.


Evidence for Use in Managing Symptoms of Severe Acne

The evidence base for severe acne consists primarily of Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies explored changes in Inflammatory and Non-inflammatory Lesion Counts in adolescent and adult populations. Findings derived from recent trials often focus on newer derivatives of the tetracycline class. Long-term outcomes past six months are not fully established, and data on prolonged use remains an area for further clarification.


Evidence for Use in Managing Inflammatory Symptoms of Rosacea

Research examining inflammatory symptoms associated with rosacea includes RCTs and Systematic Reviews, monitoring changes in Inflammatory Lesion Counts in adult patients with the papulopustular form (PPR). Evidence is often generalized from studies focused on specific, low-dose derivatives of the class. Limited evidence exists describing the measured patterns over extended follow-up durations.


Research Gaps and Follow-up Assessments

The primary research evidence is largely derived from studies including adults and adolescents. Research was studied for use in older adult populations with infections, though sample sizes were modest. Data for groups such as pediatric or pregnancy-related populations are often restricted or limited in scope in the research records. The follow-up durations were limited in many studies, meaning that the full picture of long-term outcomes is not fully established.

Key Studies & References

  1. Treatment of Rickettsia spp. infections: a review
  2. Efficacy and safety of antibiotic agents in the treatment of rosacea: a systemic network meta-analysis
  3. Tetracyclines in the Modern Era: Global Consumption, Antimicrobial Resistance, Environmental Occurrence, and Degradation Techniques

Frequently Asked Questions (FAQ)

Common questions about Tetrasol (FAQ)


Q: Why is Tetrasol taken differently than other similar treatments?

A: Official information emphasizes that Tetrasol must be taken while sitting or standing and with a full glass of water. This requirement is cited in official documents as necessary to achieve proper administration and help minimize the risk of irritation to the esophagus.


Q: Do many people take Tetrasol long-term?

A: Official labeling documents that Tetrasol is sometimes used for long-term treatment of certain conditions, such as acne. However, official data on long-term outcomes is documented as not fully established, and the full safety profile for prolonged use continues to be explored in regulatory records.


Q: Is it common to feel tired or dizzy when taking Tetrasol?

A: Official documents note that dizziness has been documented as a possible side effect of Tetrasol. Feelings of unusual tiredness or weakness have also been reported in clinical experience with the medication.


Q: Is Tetrasol safe for use in older adults?

A: The official guidelines do not list older adults as a contraindicated group. However, impaired kidney function is noted in regulatory information as potentially requiring a dose modification to help avoid systemic accumulation of the medication, which is a consideration for older age groups.


Q: Can Tetrasol be crushed, chewed, or split?

A: The product is formulated as a Soluble Powder that is designed to be fully dissolved in a liquid vehicle before ingestion. The regulatory guidance specifies the exact preparation process required to achieve proper absorption and maintain the intended safety profile.


Q: What does 'contraindication' mean in relation to Tetrasol?

A: A contraindication is a reason officially documented in regulatory documents to withhold a medical treatment due to documented risks associated with its use. For Tetrasol, this includes, for example, known hypersensitivity to the drug or severe renal impairment.


Q: Is Tetrasol available in different strengths?

A: According to official product labeling, the active ingredient Tetracycline Hydrochloride is available in multiple package sizes, commonly including 250 mg and 500 mg strengths for oral administration.


Q: What is the full list of ingredients in Tetrasol tablets/capsules?

A: Tetrasol is primarily a Soluble Powder, not a tablet or capsule. Its primary component is the active ingredient, Tetracycline Hydrochloride, alongside various inactive ingredients, known as excipients. The complete list of these excipients is documented and available in the official product labeling or Prescribing Information.


Q: Does Tetrasol cause any changes to skin or hair?

A: Official regulatory documents include effects on the skin, such as photosensitivity, which is an exaggerated sunburn reaction. Additionally, side effects such as nail discoloration have also been reported in official clinical experience.


Q: How is the long-term safety of Tetrasol monitored after it is approved?

A: After a drug is approved, regulatory authorities continue to monitor its safety profile through post-marketing surveillance programs. These systems are designed to collect and analyze reports of documented adverse events from healthcare professionals and the public to enable ongoing safety assessment.


Q: Is Tetrasol considered a common or specialty medication?

A: The World Health Organization (WHO) officially includes the active ingredient, Tetracycline, on its List of Essential Medicines. This classification indicates that the medicine is considered a basic and highly important medication necessary for a functional health system.


Q: Can Tetrasol be used for anything other than its main approved purpose?

A: The official documentation for Tetrasol strictly lists the uses for which the drug has been formally indicated and approved by regulatory bodies. Only the uses for which the drug has been formally indicated and approved are contained in the official documentation.


Q: Is Tetrasol a controlled substance or habit-forming?

A: Tetrasol is classified as an antibiotic and is not listed as a controlled substance by regulatory agencies such as the U.S. Drug Enforcement Administration (DEA). The medication is not considered to be habit-forming.


Q: If I stop taking Tetrasol, how long does it stay in my system?

A: The official pharmacokinetic data indicates that the half-life of Tetrasol is approximately 6 to 11 hours. A drug's half-life is the time it takes for the amount of active substance in the body to be reduced by half.


Q: Can I take Tetrasol if I am already taking over-the-counter pain relievers?

A: Official information notes a possibility of interaction with certain classes of pain relievers, such as NSAIDs, and documentation should be consulted regarding taking them together. The official labeling does not include every single over-the-counter pain reliever.


Q: Are there any specific vitamins or supplements that interact with Tetrasol?

A: Yes, official regulatory documents warn that products containing metallic cations, specifically iron and zinc, can significantly interfere with how Tetrasol is absorbed into the body. The regulatory requirement is that products containing these cations should be separated from a Tetrasol dose by a minimum of two hours.


Q: Is Tetrasol the first-line treatment, or is it typically used after other drugs have failed?

A: Regulatory guidance indicates that Tetrasol is often reserved for infections where other anti-infectives are documented as being contraindicated or ineffective. It is also used when susceptibility testing confirms that the bacteria causing the infection are susceptible to it.


Q: Where can I find the official prescribing information for Tetrasol?

A: The complete and official prescribing information for Tetrasol is published by the drug manufacturer and made available on governmental websites, such as the DailyMed service provided by the NIH.


Q: Is Tetrasol a generic drug, or is it only available as a brand name?

A: The active ingredient, Tetracycline Hydrochloride, is available in both generic and brand-name versions. Official drug information confirms that both formulations are recognized and regulated.


Q: If I miss a dose of Tetrasol, what is the general recommendation?

A: The general guidance found in patient instructions is to take the missed dose as soon as it is remembered. However, the official guidance is to skip the missed dose if it is nearly time for the next scheduled dose.


Q: Does Tetrasol affect a person's ability to drive or operate machinery?

A: The official warning is that side effects such as dizziness and headache may affect the ability to safely drive or operate machinery. This information is included in patient safety documentation.


Q: Can people with diabetes use Tetrasol?

A: Official information notes that Tetrasol may increase the blood-sugar-lowering effects of insulin and certain other diabetes medications. The possibility of such interaction is a consideration noted in the regulatory documents.


Q: What happens if Tetrasol doesn't seem to be working for me?

A: Regulatory guidance emphasizes the importance of completing the full prescribed course of therapy. Official guidelines note the importance of consulting a healthcare professional if symptoms do not improve or if they worsen.


Q: Does Tetrasol require any special monitoring?

A: Official documentation recommends that organ function may need monitoring, especially during prolonged periods of use. Monitoring of serum tetracycline levels may be necessary during extended therapy.


Q: Can Tetrasol interact with alcohol?

A: Official patient safety information contains a warning about limiting or avoiding alcohol consumption due to the potential for increased side effects like dizziness.


Q: Do regulatory agencies classify Tetrasol as having a high risk of drug dependency?

A: No, regulatory agencies classify Tetrasol as a broad-spectrum antibiotic. It is not listed or classified as a substance with a known high risk of drug dependency.

How should Tetrasol be stored and disposed of?

How to Store and Dispose of Tetrasol?

The storage conditions for Tetrasol Soluble Powder are strictly defined in regulatory labeling to maintain stability. The product must be stored at room temperature (e.g., at or below 25°C) in a cool, dry area. The container must be kept tightly closed and the powder must be protected from light and moisture, as it is hygroscopic.

Handling and Stability Constraints

The label mandates that Tetrasol must be kept away from heat, sparks, or flame and out of reach of children. Solutions prepared for use are generally not stable for more than 24 hours and must be prepared fresh daily. Disposal must be carried out according to all local and national regulations, with the product strictly prohibited from entering the sewage system or water courses.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tetrasol found in:

A-Z Index: